Structure Therapeutics Heads to ADA 2026 With Oral Aleniglipron: 16.3% Weight Loss at 44 Weeks, Phase 3 Planned for Q3
Structure Therapeutics will present five obesity and diabetes studies at ADA 2026, anchored by its once-daily oral small-molecule GLP-1 aleniglipron, which posted up to 16.3% placebo-adjusted weight loss at 44 weeks in the Phase 2 ACCESS II trial, among the highest reported for an oral GLP-1. The company has FDA end-of-Phase-2 alignment and plans to start a Phase 3 obesity trial in Q3 2026, with amylin and combination data also on the slate.